Bicara Therapeutics closed at $8.89 on Nov 4, down 0.78%, 70.8% below its 52-week closing high. Volume of 1.1M shares was 0.52× its 20-day average (below normal).
Split-adjusted performance: -46.3% over one month, -62.6% over six months, -44.4% over one year.
Short interest was 10.3M shares at the Oct 15 settlement, down 3.7% from the prior report (23.9% of float, 11.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BCAXBicara Therapeutics | $8.89 | −0.78% | −62.6% | — | — | — | $588.3M | |
| DMACDiaMedica Therapeutics | $10.77 | +7.70% | +65.2% | — | — | — | $580.8M | Compare |
| NVCTNuvectis Pharma | $18.47 | −4.50% | +84.7% | — | — | — | $602.9M | Compare |
| ACRSAclaris Therapeutics | $3.68 | −1.60% | −23.0% | −8.3% | −1320.1% | — | $570.3M | Compare |
| IRWDIronwood Pharmaceuticals, Inc. - | $3.77 | +7.71% | −21.9% | +32.6% | 45.4% | 4.8 | $623.0M | Compare |
| NGNENeurogene | $27.58 | +3.41% | −14.7% | — | — | — | $551.9M | Compare |
| PBYIPUMA BIOTECHNOLOGY | $10.69 | +4.60% | +43.5% | +7.8% | 14.5% | 20.7 | $551.8M | Compare |
| APMDApnimed | $15.30 | +1.59% | — | — | — | — | $637.0M | Compare |
| CLYMClimb Bio | $9.33 | −4.31% | −23.6% | — | — | — | $535.9M | Compare |
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
